Valneva and Pfizer Report Results of VLA15 in P-II (VLA15-221) Trial for the Treatment of Lyme Disease
Shots:
- The P-II (VLA15-221) trial evaluates VLA15 after administration of two or three primary series doses in 585 healthy patients aged 5-17yrs. with LD
- The results showed that patients treated with VLA15 in either a two-dose schedule or three-dose schedule were found to be more immunogenic compared to adults with both vaccination schedules tested & the safety profile was similar to prior reported data in adult patients
- The companies are expected to initiate a P-III trial to evaluate VLA15 in adults & pediatric patients aged ≥5yrs. in Q3’22, based on the P-II (VLA15-221) trial. The immunogenicity & safety data support a three-dose primary vaccination schedule in pediatric patients in the P-III study
Ref: Globenewswire | Image: Valneva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
